

IMPACT OF LIPOPROTEIN LIPASE GENE POLYMORPHISMS ON SEVERITY OF CORONARY ARTERY DISEASE

Protocol of Thesis

Submitted for Partial Fulfillment of M.D. Degree
In Clinical and Chemical Pathology

By

Walaa Ahmed Yousry Mohamed Kabil
M.B.B.Ch.M.Sc. (Clinical and Chemical Pathology)
Ain Shams University

Supervised by

Professor/ Farid Adly Farid
Professor of Clinical and Chemical Pathology
Faculty of Medicine- Ain Shams University

Professor/ Manal Mohamed Abd Al Aziz
Professor of Clinical and Chemical Pathology
Faculty of Medicine- Ain Shams University

Professor/ Karim Yehia Shaheen
Professor of Clinical and Chemical Pathology
Faculty of Medicine- Ain Shams University

Doctor/ Walid Abd El- Azim El-Hammady
Assistant Professor of Cardiology
Faculty of Medicine- Ain Shams University

Doctor/ Hala Abdelal Ahmed
Lecturer of Clinical and Chemical Pathology
Faculty of Medicine- Ain Shams University

Faculty of Medicine
Ain Shams University

2013

Acknowledgement

First of all praise and thanks to ALLAH providing me with time and effort to accomplish this thesis

I wish to thank my Prof. Dr. Farid Adly Farid, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for his support throughout this work.

A special tribute and cordial thanks are paired to Prof. Dr. Manal Mohamed Abd Al Aziz, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for her authentic guidance, kind supervision to accomplish this work.

I wish to express my deep gratitude to Prof. Dr. Karim Yehia Shaheen, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University. for his enthusiasm, meticulous guidance, precious remarks and follow up throughout this work. I had the honor to work under his supervision, and his scientific remarks are beyond acknowledgement.

I am greatly indebted to Dr. Hala Abdelal Ahmed Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her continuous encouragement and sincere contribution in this work with her time and effort.

I am also greatly indebted to Dr. Walid Abd El- Azim El-Hammady, Assistant professor of Cardiology, Faculty of Medicine, Ain Shams

University for his sincere contribution in this work with his time and precious remarks.

I would like to express my profound thanks and great gratitude to **Dr. Omayma Mohamed Hassanin, Associate consultant of Clinical Pathology, Molecular Biology Department, Medical Research Center, Faculty of Medicine, Ain-Shams University Hospitals** for her sincere help, and great patience. Really, she gave me generously of her time, I would like to express my deepest thanks for her continuous encouragement, help and support.

I would like to express my deepest thanks to **Dr. Menna Allah Shaban** for her help and support.

At the end I would like to express my sincere gratitude and great indebtedness to those who gave me everything and not waiting for any reward, to my great parents, who taught me how to be a good doctor, who gave me the strength to go on through life and who are always in my back, to the soul of **my dear sister Yasmin** who taught me how to write a thesis on a computer, may God bless her soul and to **my four beautiful daughters Farah, Mariam, Lily and little Zeina** to whom I owe more than any words can express. Dear family, you are really the candle that lighten my way throughout life, hope to make you always proud of me.

Finally, my acknowledgement and love to my outstanding husband **Hisham** for his patience, support and kind help throughout my career.

List of Contents

| | Page No. |
|--|---------------------|
| Introduction | 1 |
| Aim of the work | 3 |
| I. Coronary Artery Disease | |
| A. Anatomy of Coronary Arteries | 4 |
| B. Definition and Epidemiology of Coronary Artery Disease | 6 |
| C. Classification of CAD | |
| 1. Stable Angina Pectoris | 6 |
| 2. Acute Coronary Syndrome | 7 |
| D. Pathophysiology of CAD | 9 |
| 1. Stages of Atherosclerosis Formation and Progression | 9 |
| 2. Mechanisms of Plaque Disruption | 13 |
| E. Risk Factors of CAD | |
| 1. Modifiable Risk Factors | 14 |
| 2. Non-Modifiable Risk Factors | 24 |
| 3. Other Medical Conditions | 34 |
| F. Diagnosis of CAD | |
| 1. Medical History | 33 |
| 2. Physical Examination | 33 |
| 3. Electrocardiogram | 34 |
| 4. Echocardiogram | 34 |
| 5. Coronary angiography | 36 |
| 6. Radio-isotope Myocardial Perfusion Scanning | 38 |
| 7. Laboratory Diagnosis of CAD | 38 |
| a. Pro-inflammatory Cytokines | |
| i. Interleukin-6 | 38 |
| ii. Tumour necrosis factor alpha | 40 |
| b. Markers of plaque destabilization | |
| i. Matrix metalloproteinases | 41 |
| ii. Myeloperoxidase | 41 |
| iii. Adhesion molecules | 43 |

| | |
|--|-----------|
| c. Markers of plaque rupture | |
| i. Soluble CD40 ligand | 44 |
| ii. Placental growth factor | 44 |
| iii. Pregnancy-associated plasma protein A | 45 |
| d. Acute phase reactants | |
| i. C-reactive protein | 46 |
| e. Markers of cardiac ischemia | |
| i. Ischemia-modified albumin | 48 |
| ii. Unbound free fatty acids | 49 |
| iii. Choline | 50 |
| f. Markers of cardiac necrosis | |
| i. Creatine kinase | 51 |
| ii. Creatine kinase-MB | 53 |
| iii. Cardiac troponins | 54 |
| iv. Lactate dehydrogenase | 60 |
| g. Markers of myocardial dysfunction | |
| i. Brain natriuretic peptide | 60 |
| ii. Pro-brain natriuretic peptide | 62 |
| II. Molecular Aspects of Hyperlipidemia | 63 |
| A. Definition and Classification of Hyperlipidemia | 63 |
| 1. Hyperlipidemia Type I | 67 |
| 2. Hyperlipidemia Type II | 67 |

List of Contents, Cont..

| | Page No. |
|---|---------------------|
| 3. Hyperlipidemia Type III | 71 |
| 4. Hyperlipidemia Type IV | 72 |
| 5. Hyperlipidemia Type V | 72 |
| B. Reduced HDL Cholesterol and Elevated Triglycerides | 74 |
| C. Elevated LP (a) | 75 |
| III. Lipoprotein Lipase Gene | |
| A. Structure of Lipoprotein Lipase Gene | 78 |
| B. Structure and Synthesis of LPL Enzyme | 80 |
| C. Location and Tissue Expression of LPL Enzyme | 83 |
| D. Physiological Role of LPL Enzyme | |
| 1. Role of LPL in Lipid Metabolism and Transport | 84 |
| 2. LPL Bridging Function | 84 |
| 3. Role of LPL in Vascular Smooth Muscle Cell Proliferation | 85 |
| 4. Role of LPL in Expression of TNF- α | 86 |
| E. Regulation of LPL Expression | |
| 1. Transcriptional Control | 89 |
| 2. Post-transcriptional, Translational and Post- translational Regulation | 93 |
| 3. LPL Regulation by Interactive Proteins | 96 |
| 4. Nutritional and Hormonal Regulation of LPL | 99 |

List of Contents, Cont..

| | Page No. |
|---|---------------------|
| F. Role of LPL in Atherosclerosis | 101 |
| 1. Non-Catalytic Bridging Action of Macrophage LPL | 102 |
| 2. The Catalytic Action of LPL | 102 |
| 3. LPL acting as an Atherogenic Ligand | 103 |
| 4. Anti-atherogenic Nature of LPL | 103 |
| G. LPL Gene Polymorphism | 106 |
| 1. Introduction | 106 |
| 2. Types of LPL Gene Polymorphism | 108 |
| H. Methods of Assay of LPL | |
| 1. Analytical Methods | 113 |
| 2. Molecular Methods | 119 |
| Subjects and Methods | 128 |
| Results | 150 |
| Discussion | 174 |
| Summary and Conclusion | 185 |
| Recommendations | 188 |
| References | 189 |
| Arabic Summary | |

List of Figures

| | Page No. |
|---|---------------------|
| Figure (1): Normal structure of the wall of a healthy artery | 5 |
| Figure (2): Classification of acute coronary syndrome | 8 |
| Figure (3): Fatty-streak formation | 11 |
| Figure (4): Formation of an advanced, complicated lesion of atherosclerosis | 13 |
| Figure (5): The vulnerable plaque and consequences of plaque rupture | 15 |
| Figure (6): Role of adipokines in insulin resistance and endothelial dysfunction | 23 |
| Figure (7): Domain structure of LDL receptor | 27 |
| Figure (8): Coronary angiography showing normal right coronary artery | 37 |
| Figure (9): Biochemical profile in CAD patients | 39 |
| Figure (10): Biomarkers associated with various pathophysiological processes associated with acute myocardial infarction | 40 |
| Figure (11): Troponin release after myocardial injury | 78 |
| Figure (12): LPL gene structure and proximal promoter | 79 |

List of Figures, Cont..

| | Page No. |
|---|---------------------|
| Figure (13): Structure of LPL enzyme | 83 |
| Figure (14): The JAK-STAT signaling pathway | 88 |
| Figure (15): Schematic presentation of the complex mechanisms of tissue-specific LPL regulation | 90 |
| Figure (16): Cell biology and posttranslational modifications of LPL | 95 |
| Figure (17): DNA molecule 1 differs from DNA molecule 2 at a single base-pair location | 107 |
| Figure (18): Different pathways by which LPL S447X may exert its beneficial effects | 113 |
| Figure (19): The reaction sequence of the automated method | 114 |
| Figure (20): Scheme representing the principle of Sandwich ELISA | 116 |
| Figure (21): Comparison of ELISA vs. DELFIA assay design | 117 |
| Figure (22): DELFIA technique | 118 |
| Figure (23): Schematic drawing of the PCR cycle | 121 |
| Figure (24): A point mutation leads to the formation of different single-strand conformations of the mutant DNA. | 124 |
| Figure (25): 9700 Applied Biosystem PCR thermal cycle for DNA amplification | 133 |
| Figure (26): The QIAamp DNA Blood Mini Kit Spin column extraction procedure | 137 |
| Figure (27): 2% agarose gel electrophoresis of HindIII polymorphism | 142 |
| Figure (28): 2% agarose gel electrophoresis of S447X polymorphism | 143 |
| Figure (29): Statistical comparison between different subgroups of CAD patients and control group as regards total cholesterol | 161 |

List of Figures, Cont..

| | Page No. |
|--|---------------------|
| Figure (30): Statistical comparison between different subgroups of CAD patients and control group as regards triglycerides | 162 |
| Figure (31): Statistical comparison between different subgroups of CAD patients and control group as regards HDL-cholesterol | 163 |
| Figure (32): Statistical comparison between different subgroups of CAD patients and control group as regards LDL-cholesterol | 164 |
| Figure (33) and Figure (34): Statistical comparison between observed and expected genotypes of HindIII polymorphism in all studied population | 171 |
| Figure (35) and Figure (36): Statistical comparison between observed and expected genotypes of S447X polymorphism in all studied population | 173 |

List of Tables

| | Page No. |
|--|-------------|
| Table (1): Modifiable and non-modifiable CAD risk factors | 16 |
| Table (2): The relationship between risk of developing CAD | 19 |
| Table (3): Genetic factors in lipoprotein abnormalities | 65 |
| Table (4): Fredrickson classification of hyperlipidemias | 66 |
| Table (5): Genes affecting HDL cholesterol levels | 76 |
| Table (6): Genotype and frequency of any 2 alleles on the same locus | 147 |
| Table (7): Descriptive and comparative statistics of the demographic data among all the CAD patients versus healthy controls | 155 |
| Table (8): Descriptive and comparative statistics of the laboratory data and risk ratios among all the CAD patients versus healthy controls | 156 |
| Table (9): Descriptive statistics of the demographic data among different subgroups of CAD patients | 157 |
| Table (10): Comparative statistics of the demographic data among different subgroups of CAD patients | 158 |
| Table (11): Descriptive statistics of laboratory data and risk ratios among different subgroups of CAD patients | 159 |
| Table (12): Comparative statistics of laboratory data and risk ratios among different subgroups of CAD patients | 160 |

List of Tables, Cont..

| | Page No. |
|--|-------------|
| Table (13): Descriptive and comparative statistics of the allelic frequencies of HindIII and S447X polymorphisms of the LPL gene among all CAD patients versus healthy | 165 |
| Table (14): Descriptive and comparative statistics of the genotype frequencies of HindIII and S447X polymorphisms of the LPL gene among all CAD patients versus healthy controls | 165 |
| Table (15): Comparative statistics of the blood lipid levels and calculated risk ratios according to the HindIII and the S447X polymorphisms of the LPL gene among all the studied groups | 166 |
| Table (16): Descriptive and comparative statistics of blood lipid levels and calculated risk ratios in the H ⁺ S and H ⁻ X haplotypes of the LPL gene carriers among all the studied groups | 168 |
| Table (17): Descriptive and comparative statistics among H ⁺ S and H ⁻ X haplotypes of the LPL gene carriers as regards clinically recommended blood lipid levels and risk ratio cut-off values | 169 |
| Table (18): Distribution of all studied population according to the 3 genotypes of HindIII polymorphism | 170 |
| Table (19): The observed and expected values of the HindIII polymorphism genotypes in all the studied population | 170 |
| Table (20): Distribution of all studied population according to the 3 genotypes of S447X polymorphism | 172 |
| Table (21): The observed and expected values of the S447X polymorphism genotypes in all the studied population | 172 |

List of Abbreviations

| | |
|----------------|---|
| ACB | Albumin cobalt binding |
| ACC | American college of cardiology |
| ACS | Acute coronary syndrome |
| ADAM | 9-anthryldiazomethane |
| AMI | Acute myocardial infarction |
| Angpt1 | Angiopoietin like 1 family proteins |
| ANP | Atrial natriuretic peptide |
| APOA5 | Apolipoprotein A5 |
| ApoE | Apolipoprotein E |
| AS-PCR | Allele specific polymerase chain reaction |
| ATP | Adenosine triphosphate |
| cDNA | Complementary DNA |
| CAD | Coronary artery disease |
| CETP | Cholesteryl ester transfer protein |
| CK | Creatine Kinase |
| DELFA | Dissociation enhanced lanthanide fluorescence immunoassay |
| DM | Diabetes mellitus |
| ECG | Electro-cardiography |
| EIA | Enzyme immunoassay |
| ELISA | Enzyme linked immune-sorbent assay |
| eNOS | Enzymatic nitric oxide synthase |
| ERs | Estrogen receptors |
| ESC | European Society of Cardiology |
| FCHL | Familial combined hyperlipidemia |
| FFAs | Free fatty acids |
| FFAu | Free fatty acids unbound |
| FH | Familial hypercholesterolemia |
| GAS | γ - activated site |
| GPBB | glycogen phosphorylase isoenzyme BB |
| GPIHBP1 | Glycosylphosphatidylinositol- anchored high density lipoprotein-binding protein 1 |
| HDL-c | High density lipoprotein cholesterol |
| HindIII | Hind three |
| HIV | Human immunodeficiency virus |
| HLP | hyperlipoproteinemia |
| HPLC-MS | High performance liquid chromatography-mass spectrometry |

| | |
|--------------------------|--|
| HS | Heparan sulphate |
| Hs-CRP | highly-sensitive C-reactive protein |
| HSPG | Heparan sulphate –proteoglycans |
| ICAM-1 | Intercellular adhesion molecule-1 |
| IEMA | Immuno-enzymometric assay |
| IGF | Insulin growth factor |
| IL-1 | Interleukin-1 |
| IMA | Ischemia modified albumin |
| IRMA | Immuno-radiometric assay |
| IVUS | Intravascular ultrasonography |
| JAK-STAT | Janus kinase- signal transducer and activator of transcription |
| LCAT | Lecithin cholesterol acyl transferase |
| LD | Lactate dehydrogenase |
| LDL-c | Low density lipoprotein cholesterol |
| LDLR | Low density lipoprotein receptor |
| LMF-1 | Lipase maturation factor 1 |
| Lp(a) | Lipoprotein a |
| LPL | Lipoprotein lipase |
| LRP | LDL receptor related protein |
| MAbs | Monoclonal antibodies |
| MCA | Melting curve analysis |
| MCP-1 | Monocyte chemotactic protein-1 |
| McSNP | Melting curve analysis of SNPs |
| MI | Myocardial infarction |
| MLPA | Multiplex ligation- dependent probe amplification assay |
| MMP | Matrix metalloproteinase |
| MOH | Ministry of health |
| MPO | Myeloperoxidase |
| MTHFR | Methylenetetrahydrofolate reductase |
| NADPH⁺ | Nicotinamide dinucleotide phosphate |
| NCEP-ATP III | National cholesterol education program and adult treatment panel III |
| NSTEMI | Non-ST-segment elevation myocardial infarction |
| PAI-1 | Plasminogen activator inhibitor -1 |
| PAPP-A | Pregnancy-associated plasma protein A |
| PDGF | Platelet derived growth factor |
| PHP | post heparin plasma |
| PI3K | phosphoinositol 3 phosphate |
| PKC | Protein kinase C |

| | |
|--------------------------------|--|
| PLCHO | Plasma choline |
| PLGF | Placental growth factor |
| PPAR | Peroxisome proliferator activated receptor |
| PPRE | Peroxisome proliferator response element |
| RAP | receptor associated protein |
| RFLP-PCR | Restriction fragment length polymorphism – polymerase chain reaction |
| S447X | Ser 447X |
| sCD40L | Soluble CD40 ligand |
| SNP | Single nucleotide polymorphism |
| SSCP | Single strand conformation polymorphism |
| STEMI | ST elevation myocardial infarction |
| TAG | Triacylglycerol |
| TGF-β | Transforming growth factor beta |
| TGs | Triglycerides |
| TNF-α | Tumour necrosis factor alpha |
| TnT | Troponin T |
| EPIC | European prospective investigation into cancer and nutrition |
| tPA | tissue plasminogen activator |
| TRF | Time-resolved fluorometry |
| UA | unstable angina |
| VCAM-1 | Vascular cellular adhesion molecule-1 |
| VLDL | Very low density lipoproteins |
| VSMCs | Vascular smooth muscle cells |
| WBCHO | Whole-blood choline |
| WHO | World health organization |